LifeVantage Corporation
LFVNConsumer DefensiveNASDAQPackaged Foods · Last scanned Jul 22, 2026
Scan Results
Daily timeframeLifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and. At a $80.7M market cap, LifeVantage Corporation ranks as a micro-cap company within consumer defensive. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular h.
Market Cap
$80.7M
Beta
0.76
P/E (TTM)
13.91
P/E (Fwd)
14.01
EPS (TTM)
$0.46
EPS (Fwd)
$0.46
ROE
17.1%
ROA
6.4%
Cash
$12.5M
Total Debt
$10.2M
Free CF
$2.0M
52W Change
-50.7%
Annual Financials
Cash vs Debt
Where LFVN stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, LFVN finished 8.39% above its 150-day moving average ($5.72) and 0.64% below its 200-day moving average ($6.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFVN overbought or oversold?
At the July 15, 2026 close, LFVN's RSI(14) was 50.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $12.5M in cash and $10.2M in debt, LFVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $2.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 17.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $206.4M to $228.5M.
Investors considering LifeVantage Corporation should weigh the typical risks associated with LFVN's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for LifeVantage Corporation and its sector.